A mutation in plasma platelet-activating factor acetylhydrolase (Val279→Phe) is a genetic risk factor for stroke

Stroke

Volumn 28, Issue 12, 1997, Pages 2417-2420

  Hiramoto, Makoto ^a   Yoshida, Hidemi ^a   Imaizumi, Tadaatsu ^a   Yoshimizu, Nobuhiro ^b   Satoh, Kei ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Yokohama General Hospital   (Japan)

Author keywords

Cerebral thrombosis; Mutation; Platelet activating factor; Risk factors

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE;

ADULT; AGED; ARTICLE; DNA DETERMINATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; OCCLUSIVE CEREBROVASCULAR DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STROKE;

EID: 0031441296     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.12.2417     Document Type: Article

References (33)

1. Imaizumi T, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor: a mediator for clinicians. J Intern Med. 1995;238:5-20.
2. Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Z, Sakata S, Araki Y, Matsumoto M. Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest. 1988;82:1983-1991.
3. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, Imaizumi T, Takamatsu S, Zimmerman GA, McIntyre TM, Gray PW, Prescott SM. Platelet-activating factor acetylhydrolase deficiency: a missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest. 1996;97:2784-2791.
4. Yoshida H, Satoh K, Koyama M, Hiramoto M, Takamatsu S. Deficiency of plasma platelet-activating factor acetylhydrolase: roles of blood cells. Am J Hematol. 1996;53:158-164.
5. Satoh K, Yoshida H, Imaizumi T, Takamatsu S, Mizuno S. Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke. Stroke. 1992;23:1090-1092.
6. Satoh K, Imaizumi T, Kawamura Y, Yoshida H, Takamatsu S, Takamatsu M. Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension. Prostaglandins. 1989;37:673-682.
7. Satoh K, Imaizumi T, Kawamura Y, Yoshida H, Takamatsu S, Mizuno S, Shoji B, Takamatsu M. Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease. Prostaglandins. 1988;35:685-698.
8. Satoh K, Imaizumi T, Kawamura Y, Yoshida H, Hiramoto M, Takamatsu S, Takamatsu M. Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2. J Clin Invest. 1991;87:476-481.
9. Wolf PA, Kannel WB, McGee DL. Epidemiology of strokes in North America. In: Barnett HJM, Stein BM, Mohr JP, Yatsu FM, eds. Stroke: Pathophysiology, Diagnosis, and Management. New York, NY: Churchill Livingston; 1986:19-29.
10. Whisnant JP, Basford JR, Bernstein EF, Cooper ES, Dyken ML, Easton JD, Little JR, Marler JR, Millikan CH, Petito CK, Price TR, Raichle ME, Robertson JT, Thiele B, Walker MD, Zimmerman RA. Classification of Cerebrovascular Diseases III. Stroke. 1990;21: 637-676.
11. Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: purification and properties. J Biol Chem. 1987;262:4223-4230.
12. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsh G, Schimpf B, Hooper S, Trong HL, Cousens LS, Zimmerman GA, Yamada Y, McIntyre TM, Prescott SM, Gray PW. Anti-inflammatory properties of platelet-activating factor acetylhydrolase. Nature. 1995;374:549-553.
13. Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM. Mammalian platelet-activating factor acetylhydrolase. Biochim Biophys Acta. 1996;1301:161-173.
14. Tetta C, Bussolino F, Modena V, Montrucchio G, Segoloni G, Pescarmona G, Camussi G. Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol. 1990; 91:244-256.
15. Graham RM, Stephens CJ, Sturm MJ, Taylor RR. Plasma platelet-activating factor degradation in patients with severe coronary artery disease. Clin Sci. 1992;82:535-541.
16. Stephens CJ, Graham RM, Sturm MJ, Richardson M, Taylor RR. Variation in plasma platelet-activating factor degradation and serum lipids after myocardial infarction. Coron Artery Dis. 1993;4: 187-193.
17. Graham RM, Stephens CJ, Silvester W, Leong LL, Sturm MJ, Taylor RR. Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care Med. 1994;22: 204-212.
18. Endo S, Inada K, Yamashita H, Takakuwa T, Nakae H, Kasai T, Kikuchi M, Ogawa M, Uchida K, Yoshida M. Platelet-activating factor (PAF) acetylhydrolase activity, type II phospholipase A2, and cytokine levels in patients with sepsis. Res Commun Chem Pathol Pharmacol. 1994;83:289-295.
19. Muirhead EE. Antihypertensive functions of the kidney. Hypertension. 1980;2:444-464.
20. Kamitani T, Katamoto M, Tatsumi M, Katsuta K, Ono T, Kikuchi H, Kumada S. Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholine. Eur J Pharmacol. 1984;98:357-366.
21. Piper PJ, Stewart AG. Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4. Br J Pharmacol. 1986;88:595-605.
22. Zimmerman GA, McIntyre TM, Mehra M, Prescott SM. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol. 1990;110:529-540.
23. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
24. Kato K, Clark GD, Bazan NG, Zorumski CF. Platelet-activating factor as a potential retrograde messenger in CA1 hippocampal long-term potentiation. Nature. 1994;367:175-179.
25. Braquet P, Spinnewyn B, Demerle C, Hosford D, Marcheselli V, Rossowska M, Bazan N. The role of platelet-activating factor in cerebral ischemic and related disorders. Ann NY Acad Sci. 1989; 559:296-312.
26. Lindsberg PJ, Yue T-L, Frericks KU, Hallenbeck JM, Feuerstein G. Evidence for platelet-activating factor as a novel mediator in experimental stroke in rabbits. Stroke. 1990;21:1452-1457.
27. Khaw K-T, Barret-Connor E. Family history of stroke as an independent predictor of ischemic heart disease in men and stroke in women. Am J Epidemiol. 1986;123:59-66.
28. Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD. A study of twins and stroke. Stroke. 1992;23:221-223.
29. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH. Familial aggregation of stroke: the Framingham study. Stroke. 1993;24: 1366-1371.
30. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995; 332:912-917.
31. Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barrett J, Lane DA, Grant PJ. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 1995;15:783-785.
32. Basum H, Corder EH, Guo Z, Lannfelt L, Corder LS, Manton KG, Winblad B, Viitanen M. Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. Stroke. 1996; 27:1310-1315.
33. Prescott SM., McIntyre TM, Zimmerman GA. The role of platelet-activating factor in endothelial cells. Thromb Haemost. 1990;64: 99-103.